Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026
The presentation of the Phase 3 LIBRETTO-432 study at ASCO 2026 is crucial for Eli Lilly as it may significantly influence the competitive landscape in the NSCLC market. The outcomes could lead to shifts in market dynamics, impacting both Retevmo's positioning and the strategies of competitors in targeted therapies.
| Drug | MOA / Company | Stage |
|---|---|---|
| Retevmo | Eli Lilly | Lead |
| RET fusion-positive NSCLC | — | Competing |
| Oncology | — | Competing |
Focal Asset
Retevmo
Company
Eli Lilly
Indication
Oncology / NSCLC
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The presentation of the Phase 3 LIBRETTO-432 study at ASCO 2026 is crucial for Eli Lilly as it may significantly influence the competitive landscape in the NSCLC market. The outcomes could lead to shifts in market dynamics, impacting both Retevmo's positioning and the strategies of competitors in targeted therapies.
Why it matters
The presentation of the Phase 3 LIBRETTO-432 study at ASCO 2026 is crucial for Eli Lilly as it may significantly influence the competitive landscape in the NSCLC market. The outcomes could lead to shifts in market dynamics, impacting both Retevmo's positioning and the strategies of competitors in targeted therapies.
What changed
Trial Update
Analysis
The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.
The presentation of the Phase 3 LIBRETTO-432 study at ASCO 2026 is crucial for Eli Lilly as it may significantly influence the competitive landscape in the NSCLC market. The outcomes could lead to shifts in market dynamics, impacting both Retevmo's positioning and the strategies of competitors in targeted therapies.
Monitor results from the LIBRETTO-432 study and subsequent market reactions post-ASCO 2026.
Related companies & assets
Companies
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.